Sandra Chan

Principal
Sandra Chan | Antitrust Competition | Charles River Associates

Sandra Chan leads CRA’s Second Request and Cloud Computing/Big Data services within the Antitrust & Competition Practice. She has over 20 years of experience in the economics of antitrust liability, damages, and mergers.

Ms. Chan specializes in health care, including competition between hospitals, physician groups and other health care providers, and health insurance companies. She routinely manages teams to analyze large health care claims data (e.g., data from health plans, hospitals, physician groups, etc.) and government health care data (e.g., state discharge data, state all-payers claims data, and Centers for Medicare & Medicaid Services data, etc.). She also has experience in a broad range of other industries, including retail, manufacturing, and technology.

Ms. Chan regularly assists clients in getting FTC/DOJ clearance for proposed mergers. This work involves defining relevant product and geographic markets, measuring market concentration and competitive intensity, evaluating conditions of entry and efficiencies, and assessing horizontal and vertical competitive effects. She is also well-versed in working with clients and merging parties to simplify the Second Request process and achieving “substantial compliance” in a timely manner. This Second Request data is often leveraged to support advocacy work.

Ms. Chan has extensive experience managing projects using large, complex data. She also co-leads CRA’s Antitrust and Competition Economics practice cloud computing team to ensure that we can quickly process and analyze the ever-growing data sizes.

Selected engagements

  • 01
    Testimony in health care breach of contract and damages matter
    CRA experts provided testimony in support of Steward Health Care Network’s effort to refute breach of contract, tortious interference, unfair and deceptive...
    View engagement
  • 02
    Most favored nations (MFN) litigation
    CRA provided testimony on behalf of plaintiff in litigation regarding a health plan’s use of MFN clauses with hospitals. CRA identified several mechanisms by...
    View engagement
  • 03
    Marketing of off-label uses of blockbuster pharmaceutical
    A CRA expert was retained to analyze class certification issues relating to allegations that a pharmaceutical product was marketed for off-label uses and...
    View engagement

Credentials